Sophiris Bio Corp.

1258 Prospect St, La Jolla, California, United States

Clinical Trials

1 active

Approvals

Total approvals

Agencies

Regulatory bodies

Founded

N/A

Overview

Trial Phase Distribution

Phase

Trials

Phase 2

55.6%

Phase 1

33.3%

Phase 3

11.1%

Trial Status Distribution

Active, not recruiting

11.1%

Completed

77.8%

Withdrawn

11.1%

Clinical Trials

Trials sponsored by this organization (9)

Intraprostatic PRX302 Injection to Treat Localised Prostate Cancer

Phase 2

Completed

interventional

Jun 201738 participants

Evaluate, Safety and Tolerability of Intraprostatic PRX302 Administration, Low to Intermediate Risk Prostate Cancer

Phase 2

Completed

interventional

Jul 201518 participants

A PRX302 (protein) injection directly into the prostate to treat prostate cancer that has not spread beyond the prostate

Phase 1

Active, not recruiting

Oct 201420 participants

Randomized, Double-Blind, Vehicle-Controlled, Multicenter Safety and Efficacy Study of Intraprostatic PRX302 for LUTS BPH

Phase 3

Completed

interventional

Oct 2013479 participants

Study of PRX302 for Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia (BPH)

Phase 1

Completed

interventional

Sep 201140 participants

Convection Enhanced Localized Administration of PRX321 With Real-time Imaging for Therapy of Recurrent Glioblastoma (CLARITY-1)

Transperineal Intraprostatic Injection of PRX302 Under Ultrasound Guidance for Management of Prostatic Hyperplasia

Phase 2

Completed

interventional

Jan 200992 participants

An Open-Label, Multi-Center, Phase IIa Trial of PRX302 Treatment of Patients With Locally Recurrent Prostate Cancer After Primary Radiation Therapy

Phase 2

Completed

interventional

Feb 200830 participants

Page 1 of 2

Approvals

No approval data available

News

No news articles found

Back to Organizations